Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Familial Cancer
Published in: Familial Cancer 4/2016

01-10-2016 | Original Article

Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families

Authors: Janice P. Dutcher, Peter H. Wiernik, Leticia Varella, Rangaswamy Chintapatla

Published in: Familial Cancer | Issue 4/2016

Login to get access

Abstract

The relationship between renal cell cancer (RCC) and hematologic malignancy (HM) in the same individual has been reported for more than 20 years, and is noted in SEER database studies. Family histories suggest a familial association as well. This study evaluates the occurrence of renal cell cancer and hematologic malignancies in individual patients and families, and the occurrence of age-of-onset anticipation among generations. Family history data from our familial patient registry, including more than 700 pedigrees of familial hematologic malignancies, and 700 patients with renal cell cancer, were reviewed. Twenty-six patients with a personal history of both RCC and HM are reported. Seventy four patients with RCC are noted to have 95 family members with HM. Consistent with past reports, there was male predominance among the patients with both diseases (71 %), and among the RCC patients’ relatives with HM (57 %). Also consistent was a predominance of lymphoid malignancies in those with both diseases (92 %) and in the HMs among family members of RCC patients (79 %). The majority (95 %) of HM relatives were first or second degree relatives of the patient with RCC. Thirty of 34 parent/child pairs demonstrated age of onset anticipation in which the child developed either disease at a younger age than the parent. The co-occurrence of RCC and HM in the same patient has been shown to be significantly greater than expected. Families also appear to have an increased association. The appearance of anticipation suggests that genetic factors may be significant in this association of RCC and HM.
Literature
1.
Travis LB, Curtis RE, Boice JD Jr, Hankey BF, Fraumeni JF Jr (1991) Second cancers following non-Hodgkin’s lymphoma. Cancer 67:2002–2009CrossRefPubMed
2.
Travis LB, Curtis RE, Glimelius B, Holowat YE, van Leeuwen FE, Lynch CF, Adami J, Gospodarowicz M, Wacholder S, Inskip P (1993) Second cancers among long-term survivors of non-Hodgkin’s lymphoma. J Natl Cancer Inst 85:1932–1937CrossRefPubMed
3.
Ohsawa M, Hashimoto M, Yasunaga Y, Shingu N, Aozasa K (1998) Characteristics of non-Hodgkin’s lymphoma complicated by renal cell malignancies. Oncology 55:482–486CrossRefPubMed
4.
Anderson CM, Puszatai L, Palmer JL, Cabanillas F, Ellerhorst JA (1998) Coincidental renal cell carcinoma and non-Hodgkin’s lymphoma: the M.D. Anderson experience and review of literature. J Urol 159:714–716CrossRefPubMed
5.
Tihan T, Filippa D (1996) Coexistence of renal cell carcinoma and malignant lymphoma: a causal relationship or coincidental occurrence. Cancer 77:2325–2339CrossRefPubMed
6.
Kunther A, Wiernik PH, Dutcher JP (2006) Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature. Am J Hematol 81:271–280CrossRef
7.
Dutcher JP, Wiernik PH (2011) Renal cell carcinoma and hematologic malignancy in the same patients. J Invest Med 59:634 (abst)
8.
Dutcher JP, Wiernik PH (2015) Renal cell carcinoma (RCC) in patients with a personal or family history of hematologic malignancies (HM). Clin Adv Hematol Oncol 13:257–260PubMed
9.
Nishikubo C, Kunkel LA, Figlin R, Belldegrun A, Rosen P, Elashoff R, Wang H, Territo MC (1996) An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Cancer 78:2421–2427CrossRefPubMed
10.
Kurtz JE, Andres E, Maloisel F, Herbrecht R, Dufour P (1999) Renal cell carcinoma and type B lymphomatous proliferation: a fortuitous association? Rev Med Intern 20:329–332CrossRef
11.
Bernie JE, Albers L, Baird S, Parsons CL (2000) Synchronous ipsilateral renal adenocarcinoma, transitional cell carcinoma of the renal pelvis and metastatic renal lymphoma. J Urol 164:773–774CrossRefPubMed
12.
Shah SA, Ormerod AD, Husain A, Kohle P, Culligan D (1999) Primary cutaneous CD30 (Ki-1) positive anaplastic large cell lymphoma associated with renal cell carcinoma. Br J Dermatol 140:971–972CrossRefPubMed
13.
Shah IA, Haddad FS, Gani OS, Alfsen CC (1997) An association between renal cell carcinoma and lymphoid malignancies: a case series of eight patients. Correspondence. Cancer 80:1005–1006CrossRefPubMed
14.
Wang BY, Strauchen JA, Rabinowiz D (2001) Renal cell carcinoma with intravascular lymphomatosis. A case report of unusual collision tumours with review of literature. Arch Pathol Lab Med 125:1239–1241PubMed
15.
Yagisawa K, Ohno Y, Toba K, Tsuchiyama J, Suzuki N, Nikkuni K, Aoki S, Aizawa Y (2001) Three cases of malignant lymphoma accompanied by renal cell carcinoma. Rinsho Ketsueki 42:616–620PubMed
16.
Barista I (1997) An association between renal cell carcinoma and lymphoid malignancies. Cancer 80:1004–1005CrossRefPubMed
17.
Hanawa Y, Tanomogi H, Hasegawa S (1999) Renal cell carcinoma in a patient with malignant lymphoma: a case report. Hinyokika Kiyo 45:843–845PubMed
18.
Marquez-Moreno AJ, Manas-Uxo J, Amores-Ramirez F, Aquilar Cuevas R, Ortega Jiménez MV, Leiva Vera C, Pérez Rodriguez D (2003) Synchronous chromophobe renal carcinoma and centrocytic lymphoma. Arch Esp Urol 56:415–417PubMed
19.
Takagi Y, Senda M, Tanaka J (2000) Renal cell carcinoma in a patient with malignant lymphoma: a case report. Hinyokika Kiyo 46(8):545–547PubMed
20.
Fernandez-Pello S, Rodrigues-Villamil L, Gonzalez-Rodriguez I, Venta V, Cuervo J, Menéndez CL (2013) Lymph node non-Hodgkin’s lymphoma incidentally discovered during a nephrectomy for renal cell carcinoma. World J Clin Cases 1:121–123CrossRefPubMedPubMedCentral
21.
Bhandari MS, Mazumder A, Jagannath S, Vesole DA (2008) Association between renal cell carcinoma and plasma cell dyscrasias: a case series of six patients. Clin Lymphoma Myeloma 8:188–190CrossRefPubMed
22.
Aljitawi OS, Allen M, Zhang D, Dasouki M, Abhyankar S, Ganguly S, McGuirk JP, VanVeldhuizen P (2012) Coexistent non-Hodgkin’s lymphoma and renal cell carcinoma in a patient with von Hippel–Lindau disease: a case report. J Blood Lymph. doi:10.​4172/​2165-7831.​1000101
23.
Hwang SM, Kuyava JM, Grande JP, Swetz KM (2015) Metastatic renal cell carcinoma mimicking diverticulitis in a patient with chronic lymphocytic leukaemia. BMJ Case Rep bcr2014206161
24.
Sargin G, Yavasoglu I (2013) Renal cell carcinoma and chronic lymphocytic leukemia. Med Oncol 30:547–548CrossRefPubMed
25.
Solovan C, Smiszek R, Wickenhauser C, Chitikariu E (2013) Postoperative pyoderma gangrenous in association with renal cell carcinoma and chronic lymphocytic leukemia. Infect Dis Ther 2:75–80CrossRefPubMedPubMedCentral
26.
27.
Serefhanoglu S, Buyukasik Y, Goker H, Akin SC, Akin S, Sayinalp N, Haznedaroglu IC, Ozcebeo L (2010) Concomitant renal cell carcinoma and lymphoid malignancies: a case series of five patients and review of the literature. Med Oncol 27:55–58CrossRefPubMed
28.
Thway K, Freeman A, Woodhouse CR, Fisher C (2008) Epithelial–stromal tumor of seminal vesicle in a patient with chromophobe renal cell carcinoma and small lymphocytic lymphoma. Ann Diagn Pathol 12:433–499CrossRefPubMed
29.
Schafernak KT, Yang XJ, Hsueh W, Leestma JZ, Stagl J, Goldman S (2007) Pediatric renal cell carcinoma as second malignancy: reports of two cases and a review of the literature. Can J Urol 14:3739–3744PubMed
30.
Sakai A, Kawano M, Kuramoto A (1991) Interleukin-6 produced by renal cell carcinoma cells and progression of multiple myeloma. N Engl J Med 324:1893–1894CrossRefPubMed
31.
Prosvic P, Dulicek P, Odrazka K, Navratilová J, Morávek P, Veselský Z (2003) Asynchronous occurrence of three neoplastic diseases: chronic B-cell lymphatic leukemia, renal carcinoma and prostatic carcinoma. Rozhi Chir 82:583–586
32.
Licci S, Brenna A, Abbate I, Ascani S (2008) The association between non-Hodgkin lymphoma and renal cell carcinoma in an HIV-positive patient: clinico-pathological features and pathogenic implications. Am J Hematol 83:759CrossRefPubMed
33.
Dincol D, Arican A, Ensari A, Akyar S, Bedűk Y, Cenqiz A (1999) Concurrent occurrence of three neoplasms including non-Hodgkin’s lymphoma, renal cell carcinoma and leiomyoma in the same kidney. Med Oncol 16:134–138CrossRefPubMed
34.
Uehara E, Tasaka T, Matsuashi Y, Suemitsu I, Tamura T, Kuwajima M, Nagai M (2001) Adrenal gland lymphoma accompanied by renal cell carcinoma. Rinsho Ketsueki 42:710–712PubMed
35.
Lolli E, Matteoni R, Barbieri A, D’Ambrosi M, Archontakis F (1998) Non-Hodgkin’s lymphoma, renal carcinoma, and meningioma. Ann Ital Chir 69:101–104PubMed
36.
Mohren M, Essbach U, Franke A, Klink A, Maas C, Markmann I, Pelza F, Jentsch-Ullrich K (2003) Acute myelofibrosis in a patient with diffuse large cell non-Hodgkin’s lymphoma and renal cancer. Leuk Lymphoma 44:1603–1607CrossRefPubMed
37.
Ceres F, Rivera F, Yague JL, Blanco J, Garcia-Rijo M, Sánchez de la Nieta MD, Alcázar R, de la Torre M (2003) Non-Hodgkin’s lymphoma, IgA nephropathy and renal cell carcinoma. Nefrologia 23:554–557PubMed
38.
Guo R, Chang L, Liu Z, Li AX, Huang Q, Ann DK, Wang HC, Lin CW, Wu X, Yuan YC, Yen Y (2011) Canonical NF-κB pathway links tumorigenesis of synchronous mantle-cell lymphoma, clear cell renal cell carcinoma, and gastrointestinal stromal tumor. J Clin Oncol 29:e257–e261CrossRefPubMed
39.
Choueiri TK, Baz RC, McFadden CM, Khasawne KM, Karam MA, Kelly M, Hussein MA (2008) An association between renal cell carcinoma and multiple myeloma: a case series and clinical implications. BJU Int 101:712–715CrossRefPubMed
40.
Wu WW, Chu JT, Nael A, Rezk SA, Romansky SG, Shane L (2014) Thyroid-like follicular carcinoma of the kidney in a young patient with history of pediatric acute lymphoblastic leukemia. Case Rep Pathol 2014:313974PubMedPubMedCentral
41.
Czarnecka AM, Oborska S, Rzepecki P, Szczylik C (2014) Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer. Future Oncol 11:17–26CrossRef
42.
Labno-Kirszniok K, Nieszporek T, Wiecek A, Helbig G, Lubinski J (2013) Acute myeloid leukemia in a 38-year-old hemodialyzed patient with von Hippel–Lindau disease. Hered Cancer Clin Pract 11:11CrossRefPubMedPubMedCentral
43.
Varoglu E, Kaya B, Sari O (2013) Chronic myeloid leukemia detected on FDG PET/CT imaging in a patient with renal cell carcinoma. Rev Esp Med Nucl Imagen Mol 32:43–45PubMed
44.
Scott M, Lawrance J, Dennis M (2012) Regression of a renal cell carcinoma following allogeneic peripheral blood stem cell transplant for acute myeloid leukaemia: evidence of a graft-versus-tumour effect without significant graft-versus-host disease. Br J Haematol 159:1CrossRefPubMed
45.
Al-Najjar F, Jarkowski A 3rd (2011) Treatment of concurrent metastatic renal cell carcinoma and chronic myelogenous leukema—easier said than done? A case report. J Oncol Pharm Pract 17:436–439CrossRefPubMed
46.
Pal SK, Gupta RK, Dosik G, Figlin RA (2009) Concomitant renal cell carcinoma and chronic myelogenous leukemia: use of a targeted approach. Curr Oncol 16:44–47CrossRefPubMedPubMedCentral
47.
Parajuli R, Altman J, Kuzel T, Perdekamp M, Tallman M (2010) Renal cell carcinoma and acute promyelocytic leukemia: a nonrandom association? Am J Hematol 85:829CrossRefPubMed
48.
Huang FS, Zwerdling T, Stern LE, Ballard ET, Warner BW (2011) Renal cell carcinoma as a secondary malignancy after treatment of acute promyelocytic leukemia. J Pediatr Hematol Oncol 23:609–611CrossRef
49.
Varella L, Chintapatla R, Wiernik PH, Dutcher JP (2012) Association of renal cell carcinoma and hematologic malignancies. Br J Urol 110(Suppl 2):10–11 (abst)
50.
Chintapatla R, Varella L, Wiernik P, Rusciano V, Dutcher JP (2012) Association of renal cell carcinoma and B-cell hematologic malignancy. Blood 120(Suppl) (epub) (Abst 5086)
51.
Varella L, Chintapatla R, Wiernik PH, Rusciano V, Dutcher JP (2013) Association of renal cell and hematologic malignancies. J Clin Oncol 31(suppl):204 (abst 449)
52.
Alexandrescu DT, Wiernik PH (2007) The influence of parental age and gender on anticipation in familial B-cell malignancies. Med Oncol 24:55–67CrossRefPubMed
53.
54.
55.
Wiernik PH, Wang SQ, Hu XP, Marino P, Paietta E (2000) Age of onset evidence for anticipation in familial non-Hodgkin’s lymphoma. Br J Haematol 108:72–79CrossRefPubMed
56.
Singer EA, Bratslavsky G, Middelton L, Srinivasan R, Linehan WM (2011) Impact of genetics on diagnosis and treatment of renal cancer. Curr Urol Rep 12:47–55CrossRefPubMedPubMedCentral
57.
Seizinger BR, Rouleau GA, Ozelius LJ, Lane AH, Farmer GE, Lamiell JM, Haines J, Yuen JW, Collins D, Majoor-Krakauer D (1988) Von Hippel Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature 332:268–269CrossRefPubMed
58.
Seizinger BR, Smith DI, Filling-Katz MR, Neumann H, Green JS, Choyke PL, Anderson KM, Freiman RN, Klauck SM, Whaley J (1991) Genetic flanking markers refine diagnostic criteria and provide insights into the genetics of Von Hippel Lindau disease. Proc Natl Acad Sci USA 88:2864–2868CrossRefPubMedPubMedCentral
59.
Whaley JM, Naglich J, Gelbert L, Lamiell JM, Green JS, Collins D, Neumann HP, Laidlaw J, Li FP (1994) Germ-line mutations in the von Hippel–Lindau tumor suppressor gene are similar to somatic von Hippel–Lindau aberrations in sporadic renal cell carcinoma. Am J Hum Genet 55:1092–1102PubMedPubMedCentral
60.
Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DY, Lee S, Pause A, Dudley CF, Latif F, Kuzmin I, Schmidt L, Duh FM, Stackhouse T, Chen F, Kishida T, Wei MH, Lerman MI, Zbar B, Klausner RD, Linehan WM (1996) Molecular cloning of the von Hippel–Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta 1242:201–210PubMed
61.
Toujani S, Dessen P, Ithzar N, Danglot G, Richon C, Vassetzky Y, Robert T, Lazar V, Bosq J, De Costa L, Pérot C, Ribraq V, Patte C, Wiels J, Bernheim A (2009) High resolution genome-wide analysis of chromosomal alterations in Burkitt’s lymphoma. PLoS ONE 4:e7089CrossRefPubMedPubMedCentral
62.
Farley N, Schmidt LS, Mester JL, Peña-Llopis S, Pavia-Jimemez A, Christie A, Vocke CD, Ricketts CJ, Peterson J, Middleton L, Kinch L, Grishin N, Merino MJ, Metwalli AR, Xing C, Xie J, Dahia PL, Eng C, Linehan WM, Brugarolas J (2013) A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma. Mol Cancer Res 11(9):1061–1071CrossRefPubMedPubMedCentral
63.
64.
Wang SS, Gu YF, Wolff N, Stefanius K, Christie A, Day A, Hammer RE, Xie XJ, Rakheja D, Pedrosa L, Carroll T, McKay RM, Kapur P, Brugarolas J (2014) Bap1 is essential for kidney function and cooperates with Vhl in renal tumorigenesis. Proc Natl Acad Sci USA 111:16538–16543CrossRefPubMedPubMedCentral
65.
Schmidt LS, Junker K, Weirich G, Glenn G, Choyke P, Lubensky L, Zhuang Z, Jeffers M, Vande Woude G, Neumann H, Walther M, Linehan WM, Zbar B (1998) Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res 58:1719–1722PubMed
66.
Schmidt LS, Junker K, Nakagawa N, Kinjerski T, Weirich G, Miller M, Lubensky L, Neumann HP, Brauch H, Decker J, Vocke C, Brown JA, Jenkins R, Richards S, Bergerheim U, Gerrard B, Dean M, Linehan WM, Zbar B (1999) Novel mutations in the MET protooncogene in papillary renal carcinomas. Oncogene 18:2343–2350CrossRefPubMed
67.
Launonen V, Vierimaa O, Kiuru M, Isola J, Roth S, Pukkala E, Sistonen P, Herva R, Aaltonen LA (2001) Inherited susceptibility to uterine leiomyomas and renal cell cancer. Proc Natl Acad Sci USA 98:3387–3392CrossRefPubMedPubMedCentral
68.
Nickerson ML, Warren MB, Toro JR, Matrosova V, Glenn G, Turner M, Duray P, Merino M, Choyke P, Pavlovich CP, Sharma N, Walther M, Munroe D, Hill R, Maher E, Greenberg C, Lerman M, Linehan WM, Zbar B, Schmidt LS (2002) Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with Birt–Hogg–Dube syndrome. Cancer Cell 2:157–164CrossRefPubMed
69.
Shuch B, Vourganti S, Ricketts CJ, Middleton L, Peterson J, Merino MJ, Metivalli AR, Srinivasan R, Linehan WM (2014) Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol 32:431–437CrossRefPubMed
70.
Vocke CD, Yang Y, Pavlovich CP, Schmidt LS, Nickerson ML, Torres-Cabala CA, Meriono MJ, Walther MM, Zbar B, Linehan WM (2005) High frequency of somatic frameshift BHD gene mutations in Birt–Hogg–Dube-associated renal tumors. JNCI 97:931–935CrossRefPubMed
71.
Mester JL, Moore RA, Eng C (2013) PTEN germline mutations in patients initially tested for other hereditary cancer syndromes; would use of risk assessment tools reduce genetic testing? Oncologist 18:1083–1090CrossRefPubMedPubMedCentral
72.
Shuch B, Ricketts CJ, Vocke CD, Komiya T, Middleton LA, Kaufman EC, Merino MJ, Metwalli AR, Dennis P, Linehan WM (2013) Germline PTEN mutation Cowden syndrome: an under-appreciated form of hereditary kidney cancer. J Urol 190:1990–1998CrossRefPubMedPubMedCentral
73.
Musilova K, Mraz M (2015) MicroRNAs in B-cell lymphomas: how a complex biology gets more complex. Leukemia 29:1004–1017CrossRefPubMed
74.
Papadavid E, Korkolopoulou P, Levidou G, Saetta AA, Papadaki T, Siakantaris M, Nikolaou V, Okonomidi A, Chatziandreou I, Marinos L, Kollalexi A, Stratigos A, Rigopoulos D, Psyrri A, Patsouris E, Antoniou C (2014) In situ assessment of PI3K and PTEN alterations in mycosis fungoides: correlation with clinicopathological features. Exp Dermatol 12:931–933CrossRef
75.
Cristofoletti C, Picchio MC, Lazzeri C, Tocco V, Pagani E, Bresin A, Mancini B, Pasarelli F, Facchiano A, Scala E, Lombardo GA, Cantonetti M, Caprini E, Russo G, Narducci MG (2013) Comprehensive analysis of PTEN status in Sezary syndrome. Blood 122:3511–3520CrossRefPubMed
76.
Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollbert-Wulf B, Dietze K, Nogai H, Storek B, Madle H, Dörken B, Janz M, Dimhofer S, Lenz P, Hummel M, Tzankov A, Lenz O (2013) PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 110:12420–12425CrossRefPubMedPubMedCentral
77.
Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon, or the combination of interferon plus temsirolimus for patients with advanced renal cell carcinoma and poor risk features. N Engl J Med 356:2271–2281CrossRefPubMed
78.
Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind randomized, placebo-controlled phase III trial. Lancet 372:449–456CrossRefPubMed
79.
Wiernik PH, Ashwin M, Hu XP, Paietta E, Brown K (2001) Anticipation in familial chronic lymphocytic leukemia. Br J Haematol 113:407–411CrossRefPubMed
80.
Deshpande HA, Hu XP, Marino P, Jan NA, Wiernik PH (1998) Anticipation in plasma cell dyscrasias. Br J Haematol 103:696–703CrossRefPubMed
81.
Lynch HT, Watson P, Tarantolo S, Wiernik PH, Quinn-Laquer B, Bergsagel I, Huiart L, Olopade OI, Sobol H, Sanger W, Hogg D, Weisenburger D (2005) Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23:685–693CrossRefPubMed
82.
Wiernik PH, Wickramasinghe D, Dutcher JP (2015) Families with both Hodgkin’s lymphoma and myeloma in their pedigrees. Clin Adv Hematol Oncol 13:257–260PubMed
83.
Wiernik PH, Hu X, Ratech H, Fineberg S, Marino P, Schleider MA, Etkind P, Walewski JA (2000) Non-Hodgkin’s lymphoma in women with breast cancer. Cancer J 6:336–342PubMed
84.
Etkind P, Du J, Khan A, Pillitteri J, Wiernik PH (2000) Mouse mammary tumor virus-like ENV gene sequences in human breast tumors and in a lymphoma of a breast cancer patient. Clin Cancer Res 6:1273–1278PubMed
85.
Etkind PR, Stewart AFR, Dorai T, Purcell DJ, Wiernik PH (2004) Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both breast tumors and non-Hodgkin’s lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res 10:5656–5664CrossRefPubMed
86.
Kinch A, Cavelier L, Bengtsson M, Baechlund E, Enblad G, Backlin C, Thunberg U, Sundström C, Pauksens K (2014) Donor or recipient origin of post-transplant lympho-proliferative disorders following solid organ transplantation. Am J Transplant 14:2838–2845CrossRefPubMed
87.
Gratama JW, Zea AH, Bolhuis RL, Ochoa AC (1999) Restoration of expression of signal-transduction molecules in lymphocytes from patients with metastatic renal cell cancer after combination immunotherapy. Cancer Immunol Immunother 48:263–269CrossRefPubMed
88.
Watari J, Chen N, Amenta PS, Fukui H, Oshima T, Tomita T, Miwa H, Lim KJ, Das KM (2014) Helicobacter pylori associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World J Gastroenterol 20:5461–5473CrossRefPubMedPubMedCentral
89.
90.
Sakai T, Ogura Y, Narita J, Suto T, Kimura D, Ainais S, Fujita H, Kamida M (2003) Simultaneous early adenocarcinoma and mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach associated with Helicobacter pylori infection. Gastric Cancer 6:191–196CrossRefPubMed
91.
Neri A, Barriga F, Inghirami G, Knowles DM, Neeguave J, Magrath IT, Dalla-Favera R (1991) Epstein–Barr virus infection precedes clonal expansion in Burkitt’s and acquired immunodeficiency syndrome-associated lymphoma. Blood 77:1092–1095PubMed
92.
Polz-Gruszka D, Stec A, Dworzanski J, Potz-Dacewicz M (2015) EVB, HSV, CMV and HPV in laryngeal and oropharyngeal carcinoma in Polish patients. Anticancer Res 35:1657–1661PubMed
93.
Jiang R, Ekshyyan O, Moore-Medlin T, Rong X, Nathan S, Gu X, Abreo F, Rosenthal EL, Shi M, Gudry JT, Scott RS, Hutt-Fletcher LM, Nathan CA (2015) Association between human papilloma virus/Epstein–Barr virus coinfection and oral carcinogenesis. J Oral Pathol Med 44:28–36CrossRefPubMed
94.
Tsukasaki K, Hermine O, Bazarbachi A, Ratner L, Ramos JC, Harrington W Jr, O’Mahony D, Janik JE, Bittencourt AL, Taylor GP, Yamaguchi K, Utsunomiya A, Tobinai K, Watanabe T (2009) Definition, prognostic factors, treatment and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus. J Clin Oncol 27:453–459CrossRefPubMedPubMedCentral
95.
96.
Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S (2002) Update on Kaposi’s sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman’s disease, and pleural effusion lymphoma. Lancet Infect Dis 2:344–352CrossRefPubMed
97.
Pogo BG, Melana SM, Moran H, Holland JF (2001) Presence of MMTV-like env gene sequences in human breast cancer. Breast Cancer Res Treat 125:295–297CrossRef
98.
Melana SM, Nepomnaschy I, Hasa J, Djougarian A, Holland JF, Pogo BG (2010) Detection of human mammary tumor virus proteins in human breast cancer cells. J Virol Methods 163:157–161CrossRefPubMed
99.
Stratton KL, Schrader KA, Manschreck C, Rau-Murthy R, Corines M, Dutcher J, Wiernik P, Palomba L, Portlock C, Murali R, Klein RJ, Coleman J, Stadler Z, Offit K, Vijai J (2013) Renal cell carcinoma and non-Hodgkin’s lymphoma: genomic approaches to identification of shared susceptibility. Proc Soc Urol Oncol (abst)
Metadata
Title
Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families
Authors
Janice P. Dutcher
Peter H. Wiernik
Leticia Varella
Rangaswamy Chintapatla
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Familial Cancer / Issue 4/2016
Print ISSN: 1389-9600
Electronic ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-016-9911-7

Other articles of this Issue 4/2016

Familial Cancer 4/2016 Go to the issue

Original Article

Evaluation of TP53 Pro72Arg and MDM2 SNP285–SNP309 polymorphisms in an Italian cohort of LFS suggestive patients lacking identifiable TP53 germline mutations

Original Article

Modeling the dyadic effects of parenting, stress, and coping on parent–child communication in families tested for hereditary breast-ovarian cancer risk

Original Article

CTNNB1-mutant colorectal carcinomas with immediate invasive growth: a model of interval cancers in Lynch syndrome

Original Article

Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis

Original Article

Evaluation of laboratory perspectives on hereditary cancer panels

Original Article

Patient and genetic counselor perceptions of in-person versus telephone genetic counseling for hereditary breast/ovarian cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits